Columbus, OH, United States of America

Dinesh Ahirwar

This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignee: The Ohio State University. Active years: 2017-2020.


% Patents Active = 100.0


Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 24(Granted Patents)


Company Filing History:


Years Active: 2017-2020

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Dinesh Ahirwar: Innovator in Cancer Research

Introduction

Dinesh Ahirwar is a notable inventor based in Columbus, OH (US). He has made significant contributions to the field of cancer research through his innovative inventions. With a total of 4 patents, his work focuses on advancing the understanding and treatment of metastatic cancer.

Latest Patents

Dinesh's latest patents include a groundbreaking invention titled "Galvanotaxis assay for quantitative assessment of metastatic potential of cancer cells." This system is designed to accelerate and/or inhibit the migration of cells by applying a time-varying magnetic field. The technology induces eddy currents that promote electrotaxis (galvanotaxis) of cells without the need for chemokines or glucose. This invention can also be utilized to study and quantify the metastatic potential of different cell lines.

Career Highlights

Dinesh Ahirwar is affiliated with The Ohio State University, where he continues to contribute to research and innovation in cancer treatment. His work has garnered attention for its potential to improve methodologies in assessing cancer cell behavior.

Collaborations

Dinesh collaborates with esteemed colleagues such as Vish Subramaniam and Joseph Mitchell West. Their combined expertise enhances the research efforts at The Ohio State University.

Conclusion

Dinesh Ahirwar's innovative work in cancer research exemplifies the impact of scientific advancements on healthcare. His patents and collaborations reflect a commitment to improving cancer treatment methodologies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…